Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAGED1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAGED1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAGED1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAGED1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAGED1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAGED1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAGED1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAGED1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00506781 | Colorectum | FAP | regulation of epithelial cell proliferation | 71/2622 | 381/18723 | 6.67e-03 | 4.12e-02 | 71 |
GO:00485114 | Colorectum | CRC | rhythmic process | 64/2078 | 298/18723 | 1.43e-07 | 1.62e-05 | 64 |
GO:00076234 | Colorectum | CRC | circadian rhythm | 47/2078 | 210/18723 | 1.89e-06 | 9.29e-05 | 47 |
GO:00720733 | Colorectum | CRC | kidney epithelium development | 34/2078 | 136/18723 | 3.87e-06 | 1.63e-04 | 34 |
GO:00016552 | Colorectum | CRC | urogenital system development | 62/2078 | 338/18723 | 4.67e-05 | 1.10e-03 | 62 |
GO:00719004 | Colorectum | CRC | regulation of protein serine/threonine kinase activity | 65/2078 | 359/18723 | 4.67e-05 | 1.10e-03 | 65 |
GO:00720011 | Colorectum | CRC | renal system development | 56/2078 | 302/18723 | 7.85e-05 | 1.63e-03 | 56 |
GO:00427524 | Colorectum | CRC | regulation of circadian rhythm | 28/2078 | 121/18723 | 1.17e-04 | 2.29e-03 | 28 |
GO:00018221 | Colorectum | CRC | kidney development | 54/2078 | 293/18723 | 1.23e-04 | 2.40e-03 | 54 |
GO:00458605 | Colorectum | CRC | positive regulation of protein kinase activity | 67/2078 | 386/18723 | 1.34e-04 | 2.55e-03 | 67 |
GO:00605623 | Colorectum | CRC | epithelial tube morphogenesis | 58/2078 | 325/18723 | 1.74e-04 | 3.10e-03 | 58 |
GO:00336745 | Colorectum | CRC | positive regulation of kinase activity | 77/2078 | 467/18723 | 2.42e-04 | 4.00e-03 | 77 |
GO:0001823 | Colorectum | CRC | mesonephros development | 23/2078 | 96/18723 | 2.68e-04 | 4.32e-03 | 23 |
GO:0001657 | Colorectum | CRC | ureteric bud development | 22/2078 | 91/18723 | 3.14e-04 | 4.89e-03 | 22 |
GO:00719023 | Colorectum | CRC | positive regulation of protein serine/threonine kinase activity | 39/2078 | 200/18723 | 3.20e-04 | 4.95e-03 | 39 |
GO:0072163 | Colorectum | CRC | mesonephric epithelium development | 22/2078 | 92/18723 | 3.71e-04 | 5.55e-03 | 22 |
GO:0072164 | Colorectum | CRC | mesonephric tubule development | 22/2078 | 92/18723 | 3.71e-04 | 5.55e-03 | 22 |
GO:00720091 | Colorectum | CRC | nephron epithelium development | 24/2078 | 109/18723 | 7.49e-04 | 9.60e-03 | 24 |
GO:00606881 | Colorectum | CRC | regulation of morphogenesis of a branching structure | 14/2078 | 50/18723 | 8.08e-04 | 1.02e-02 | 14 |
GO:00720061 | Colorectum | CRC | nephron development | 29/2078 | 142/18723 | 8.29e-04 | 1.04e-02 | 29 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa047221 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa047224 | Colorectum | MSS | Neurotrophin signaling pathway | 45/1875 | 119/8465 | 7.04e-05 | 6.55e-04 | 4.02e-04 | 45 |
hsa047225 | Colorectum | MSS | Neurotrophin signaling pathway | 45/1875 | 119/8465 | 7.04e-05 | 6.55e-04 | 4.02e-04 | 45 |
hsa047226 | Colorectum | FAP | Neurotrophin signaling pathway | 38/1404 | 119/8465 | 2.49e-05 | 2.78e-04 | 1.69e-04 | 38 |
hsa047227 | Colorectum | FAP | Neurotrophin signaling pathway | 38/1404 | 119/8465 | 2.49e-05 | 2.78e-04 | 1.69e-04 | 38 |
hsa047228 | Colorectum | CRC | Neurotrophin signaling pathway | 33/1091 | 119/8465 | 1.08e-05 | 3.00e-04 | 2.04e-04 | 33 |
hsa047229 | Colorectum | CRC | Neurotrophin signaling pathway | 33/1091 | 119/8465 | 1.08e-05 | 3.00e-04 | 2.04e-04 | 33 |
hsa0472225 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
hsa04722111 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
hsa0472210 | Liver | HCC | Neurotrophin signaling pathway | 74/4020 | 119/8465 | 8.27e-04 | 3.26e-03 | 1.81e-03 | 74 |
hsa0472211 | Liver | HCC | Neurotrophin signaling pathway | 74/4020 | 119/8465 | 8.27e-04 | 3.26e-03 | 1.81e-03 | 74 |
hsa0472220 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
hsa04722110 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
hsa0472224 | Oral cavity | LP | Neurotrophin signaling pathway | 46/2418 | 119/8465 | 1.07e-02 | 3.77e-02 | 2.43e-02 | 46 |
hsa0472234 | Oral cavity | LP | Neurotrophin signaling pathway | 46/2418 | 119/8465 | 1.07e-02 | 3.77e-02 | 2.43e-02 | 46 |
hsa0472218 | Prostate | BPH | Neurotrophin signaling pathway | 38/1718 | 119/8465 | 1.76e-03 | 7.16e-03 | 4.43e-03 | 38 |
hsa0472219 | Prostate | BPH | Neurotrophin signaling pathway | 38/1718 | 119/8465 | 1.76e-03 | 7.16e-03 | 4.43e-03 | 38 |
hsa0472223 | Prostate | Tumor | Neurotrophin signaling pathway | 39/1791 | 119/8465 | 2.01e-03 | 8.10e-03 | 5.02e-03 | 39 |
hsa0472233 | Prostate | Tumor | Neurotrophin signaling pathway | 39/1791 | 119/8465 | 2.01e-03 | 8.10e-03 | 5.02e-03 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGED1 | SNV | Missense_Mutation | novel | c.2408N>T | p.Pro803Leu | p.P803L | Q9Y5V3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.943) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGED1 | SNV | Missense_Mutation | rs782818810 | c.371N>T | p.Ser124Leu | p.S124L | Q9Y5V3 | protein_coding | tolerated_low_confidence(1) | benign(0.01) | TCGA-A8-A0A2-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAGED1 | SNV | Missense_Mutation | | c.2138N>C | p.Arg713Thr | p.R713T | Q9Y5V3 | protein_coding | tolerated_low_confidence(0.17) | benign(0.21) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAGED1 | SNV | Missense_Mutation | novel | c.805N>A | p.Glu269Lys | p.E269K | Q9Y5V3 | protein_coding | tolerated_low_confidence(0.28) | benign(0.175) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
MAGED1 | SNV | Missense_Mutation | novel | c.360C>A | p.Asp120Glu | p.D120E | Q9Y5V3 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.991) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGED1 | SNV | Missense_Mutation | | c.1936G>A | p.Gly646Arg | p.G646R | Q9Y5V3 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.999) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MAGED1 | SNV | Missense_Mutation | | c.680N>T | p.Asp227Val | p.D227V | Q9Y5V3 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.642) | TCGA-D8-A1JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
MAGED1 | SNV | Missense_Mutation | novel | c.2395N>T | p.Arg799Cys | p.R799C | Q9Y5V3 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.725) | TCGA-E9-A6HE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
MAGED1 | SNV | Missense_Mutation | novel | c.2461T>G | p.Phe821Val | p.F821V | Q9Y5V3 | protein_coding | tolerated_low_confidence(0.08) | probably_damaging(0.969) | TCGA-EW-A1PC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAGED1 | deletion | In_Frame_Del | novel | c.1288_1305delNNNNNNNNNNNNNNNNNN | p.Asn432_Gln437del | p.N432_Q437del | Q9Y5V3 | protein_coding | | | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |